Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.560
+0.020 (0.79%)
At close: Apr 28, 2026, 4:00 PM EDT
2.550
-0.010 (-0.38%)
After-hours: Apr 28, 2026, 6:08 PM EDT

Moleculin Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Selling, General & Admin
9.128.7910.0211.548.39
Upgrade
Research & Development
15.8917.7319.4918.9714.42
Upgrade
Operating Expenses
25.126.6429.6330.6422.97
Upgrade
Operating Income
-25.1-26.64-29.63-30.64-22.97
Upgrade
Interest & Investment Income
0.110.551.370.240.31
Upgrade
Other Non Operating Income (Expenses)
-8.560.04-1.511.386.77
Upgrade
EBT Excluding Unusual Items
-33.56-26.05-29.77-29.03-15.89
Upgrade
Pretax Income
-33.56-26.05-29.77-29.03-15.89
Upgrade
Net Income
-33.56-26.05-29.77-29.03-15.89
Upgrade
Preferred Dividends & Other Adjustments
0.1----
Upgrade
Net Income to Common
-33.66-26.05-29.77-29.03-15.89
Upgrade
Shares Outstanding (Basic)
10000
Upgrade
Shares Outstanding (Diluted)
10000
Upgrade
Shares Change (YoY)
760.13%74.28%3.60%6.43%172.97%
Upgrade
EPS (Basic)
-28.42-189.14-376.71-380.52-221.77
Upgrade
EPS (Diluted)
-28.42-189.14-376.71-380.52-221.77
Upgrade
Free Cash Flow
-22.74-23.88-23.72-27.71-18.97
Upgrade
Free Cash Flow Per Share
-19.19-173.36-300.10-363.22-264.69
Upgrade
EBITDA
-25.01-26.52-29.5-30.51-22.8
Upgrade
D&A For EBITDA
0.090.130.130.130.16
Upgrade
EBIT
-25.1-26.64-29.63-30.64-22.97
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.